Immunocore Holdings (IMCR) EBT Margin (2021 - 2026)
Immunocore Holdings (IMCR) posted quarterly EBT Margin of 12.44% for Q1 2026, up 596.0% year-on-year from 1.79% in Q1 2025, and up 182.3% on a QoQ basis from 15.12% in Q4 2025.
Immunocore Holdings (IMCR) EBT Margin (2021 - 2026) Analysis & Trends
Immunocore Holdings (IMCR) has reported EBT Margin for 6 consecutive years, with 12.44% the latest figure, recorded in Q1 2026.
- Quarterly EBT Margin rose 596.0% year-over-year to 12.44% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.89% (up 394.0% YoY) and the FY2025 annual result came in at 4.77%, up 1229.0% from the prior year.
- EBT Margin improved to 12.44% in Q1 2026 per IMCR's latest filing, from 15.12% in the prior quarter.
- Over the last five years, EBT Margin for IMCR reached as high as 12.44% in Q1 2026 and fell as low as 55.57% in Q2 2022.
- A 5-year average of 16.62% and a median of 14.28% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin jumped 55664 bps — and 2023, when it sank 1097 bps.
- Year by year, EBT Margin stood at 48.56% in 2022, then gained by 25 bps to 36.55% in 2023, then grew by 19 bps to 29.53% in 2024, then jumped by 49 bps to 15.12% in 2025, then jumped by 182 bps to 12.44% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 12.44%, 15.12%, and 0.29% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Immunocore Holdings | 1.80 Bn | 957.43 Mn | 106.24 Mn | 12.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.44% |
| Dec 31, 2025 | -15.12% |
| Sep 30, 2025 | 0.29% |
| Jun 30, 2025 | -9.90% |
| Mar 31, 2025 | 6.48% |
| Dec 31, 2024 | -29.53% |
| Sep 30, 2024 | 7.59% |
| Jun 30, 2024 | -13.44% |
| Mar 31, 2024 | -34.15% |
| Dec 31, 2023 | -36.55% |
| Sep 30, 2023 | 1.13% |
| Jun 30, 2023 | -28.15% |
| Mar 31, 2023 | -35.05% |
| Dec 31, 2022 | -48.56% |
| Sep 30, 2022 | 12.10% |
| Jun 30, 2022 | -55.57% |
| Dec 31, 2021 | -594.19% |
| Sep 30, 2021 | -544.55% |